
Feature|Videos|April 24, 2024
AUA 2024: Dr. Weiner previews key prostate cancer research
Author(s)Urology Times staff
Adam B. Weiner, MD, highlights several studies in prostate cancer set to be presented at the upcoming 2024 American Urological Association Annual Meeting.
Advertisement
In this video, Adam B. Weiner, MD, highlights 5 studies in prostate cancer that will be presented at the upcoming 2024 American Urological Association (AUA) Annual Meeting, which will take place on May 3 – 6 in San Antonio, Texas. Weiner is a current urologic oncology fellow at the University of California, Los Angeles.
During the discussion, Weiner highlights the following presentations:
- P2s: Efficacy of [177Lu]Lu-PSMA-617 versus ARPI change in taxane-naive patients with metastatic castration-resistant prostate cancer by pre-randomization ARPI (PSMAfore)
- P2s: Apalutamide and androgen deprivation therapy for the treatment of high-risk localized prostate cancer following radical prostatectomy in Apa-RP: a multicenter, open-label, single-arm ph
- PD01-03: Third interim analysis (IA3) of the DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC)
- PD01-06: Prostate-specific antigen dynamics from the phase 3 EMBARK trial: A post hoc analysis
- PD39-06: A randomized clinical trial comparing focal ablation and radical prostatectomy in patients with unilateral clinically significant prostate cancer. Intention to treat analysis at two-year follow-up
Advertisement
Related to this article

Muhammed A. Moukhtar Hammad, MBBCh, MSc, discusses real-world trends in baseline erectile dysfunction treatment across AUA sections before minimally invasive BPH procedures.

Earlier genetic testing in men with very low sperm counts may spare unnecessary testing or surgery, according to Ronald Anglade, MD.

Vignesh Packiam, MD, discusses optimizing BCG treatment in high-risk NMIBC, including patient selection for combination immunotherapy and treatment-related trade-offs.

VOLGA results raise the question of treatment de-intensification in perioperative MIBC care, according to Suzanne B. Merrill, MD, FACS.

Patient goals, disease features, and response to prior therapy guide treatment choices across high-risk NMIBC, according to Suzanne B. Merrill, MD, FACS.

Suzanne B. Merrill, MD, discusses emerging perioperative approaches in MIBC and the potential for more personalized treatment selection based on disease characteristics.

BCG monotherapy and a high-quality TURBT remain the foundation for BCG-naive high-risk NMIBC, according to Vignesh T. Packiam, MD.
Advertisement
Advertisement
Trending on Urology Times
1
Treatment interruptions in prostate cancer: Balancing PSA kinetics and quality of life
2
Cretostimogene reduces recurrence risk by 68% in phase 3 PIVOT-006 trial in NMIBC
3
Rethinking Testosterone Therapy After the FDA Label Revisions
4
American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
5




